Form 8-K · Current Report · Filed 2024-10-21
Medtronic Shareholders Elect Directors and Approve Proposals at 2024 AGM
On October 17, 2024, Medtronic plc held its Annual General Meeting of Shareholders where shareholders elected ten directors and approved several non-binding and binding proposals including the reappointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025 and the authorization to set the auditor's remuneration.
- Filer
- Medtronic plc MDT · NYSE
- Filed
- Accession
- 0001613103-24-000151
- CIK
- 0001613103
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
Additionally, shareholders approved, on a non-binding advisory basis, named executive officer compensation, renewal of the Board's authority to issue shares and to opt out of pre-emption rights, and authorized the Company and any subsidiary to make overseas market purchases of Medtronic ordinary shares.
Items reported
Submission of Matters to a Vote of Security Holders
Financial Statements and Exhibits
Market reaction
Close before filing
$92.24
Next session
-1.2%
Since filing
-7.4%
Latest close
$85.39
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MDT reporting the same item, with the next session's move:
About Medtronic plc
Medtronic plc is a leading global healthcare technology company that designs, manufactures, and sells innovative medical devices and therapies used in various medical procedures. The primary function of Medtronic is to improve healthcare outcomes by providing advanced therapeutic solutions. Its extensive product portfolio includes cardiac and vascular devices, diabetes-related products, minimally invasive therapies, and neurosurgical technologies. Medtronic plays a vital role in the medical device industry, catering to cardiovascular treatment, advanced diabetes management, spinal and musculoskeletal therapy, and more. Notably, the company is renowned for its pacemaker technology and is a pivotal player in cardiac care. The company's innovations significantly impact the healthcare sector by enhancing the quality of life for patients worldwide and improving the effectiveness of medical treatments. As a key player in the medical device market, Medtronic is instrumental in setting industry standards and advancing medical technology through continuous research and development. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic's global presence underscores its substantial contribution to the healthcare industry across various continents.
Never miss another MDT filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.